WGS
Get informed when a big investor buys or sells
+ FollowOvervalued by 297.9% based on the discounted cash flow analysis.
| Market cap | $1.93 Billion |
|---|---|
| Enterprise Value | $2.01 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.73 |
| Beta | 1.91 |
| Outstanding Shares | 29,335,126 |
| P/E Ratio | -24.48 |
|---|---|
| PEG | -2.81 |
| Price to Sales | 4.73 |
| Price to Book Ratio | 8.86 |
| Enterprise Value to Revenue | 4.53 |
| Enterprise Value to EBIT | -48.58 |
| Enterprise Value to Net Income | -26 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.66 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 47.14% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Holdings and activity of institutional investors.
| Ownership % | 6.71%▼ 99.82% |
|---|---|
| Total Invested | $135.44M▼ 93.25% |
| Investors Holding | 48▼ 205.00% |
No data
Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and g...